Serum resistance of Neisseria gonorrhoeae. Does it thwart the inflammatory response and facilitate the transmission of infection?

• Published in: Annals of the New York Academy of Sciences Vol. 730; p. 7
• Main Authors: Rice, P A, McQuillen, D P, Gulati, S, Jani, D B, Wetzler, L M, Blake, M S, Gotschlich, E C
• Format: Journal Article
• Language: English
• Published: United States 01.09.1994
• Subjects: Antibodies, Bacterial - immunology; Antigens, Bacterial - immunology; Bacterial Outer Membrane Proteins - immunology; Bacterial Proteins - immunology; Blood Bactericidal Activity; Complement C3 - metabolism; Female; Gonorrhea - immunology; Gonorrhea - transmission; Humans; Lipopolysaccharides - immunology; Male; Neisseria gonorrhoeae - immunology
• ISSN: 0077-8923
• DOI: 10.1111/j.1749-6632.1994.tb44234.x

N. gonorrhoeae differentially subvert the effectiveness of complement (C) and alter the inflammatory responses elicited in human infection. Disseminated (DGI) isolates typically resist killing by normal serum (are serum-resistant), inactivate more C3b (to iC3b preferentially bound via amide linkages), generate less C5a, and result in less inflammation at local sites. Pelvic inflammatory disease isolates are serum-sensitive, inactivate less C3b (while maintaining active C3b via stable amide linkages), generate more C5a, and result in more inflammation at local sites. Sialylation of SS gonococci, presumed to occur in vivo, converts them to serum-resistant, but it does not change the patterns of C3b inactivation and therefore may not affect local inflammation. IgG antibody directed against gonococcal reduction modifiable protein (Rmp) blocks C-mediated killing of N. gonorrhoeae. Anti-Rmp blocking antibodies may harbor specificity for OmpA sequences shared with other neisserial species or Enterobacteriaceae or may be directed against unique Rmp upstream cysteine loop specific sequences, or both. Preexisting antibodies directed against Rmp facilitate transmission of gonococcal infection to exposed women; exclusion of highly immunogenic Rmp antigens from vaccine candidates may be important.